ClinicalTrials.gg

Program

GSK4528287

A development code.

In GlaxoSmithKline's pipeline, Anti IL23-IL18 bispecific antibody. Its studies are mostly in Colitis, Ulcerative, led by GlaxoSmithKline.

Furthest: phase 1, since Nov 7, 20241 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 1since Nov 7, 2024Nov 7, 2024none ahead
  • Named in GlaxoSmithKline’s own pipeline as GSK4528287, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 7, 2024First study: phase 1 study in Colitis, UlcerativeFirst studyNCT06681181 · 48 enrolled · United Kingdom

TargetBeta

“Anti IL23-IL18 bispecific antibody”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06681181Colitis, Ulcerative · United Kingdom1Active, not recruitingApr 23, 202648

How it is read

Names in the registry

  • “GSK4528287”, 1 entry

Codes read as this program: GSK4528287.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.